United Kingdom
Every company in the roster headquartered in United Kingdom.
Every company in the roster headquartered in United Kingdom.
26 of 26 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
AstraZenecaAZN · Nasdaq | 114 assets: 36 approved, 26 Ph 3, 28 Ph 2, 20 Ph 1, 4 other | elecoglipronPhase 3 · ObesityReliable signal | 24 Nov 2026AZD0754 · Phase 1/2 | $277.3B | $7.6BMar 2026 | — | $14.6B |
GlaxoSmithKlineGSK · NYSE | 73 assets: 26 approved, 8 Ph 3, 10 Ph 2, 10 Ph 1, 19 other | VilanterolPhase 3 · AsthmaPartial signal | 23 Nov 2026Dostarlimab · Phase 2 | $104.8B | $4.6BDec 2025 | Cash-flow positive | $9.9B |
Silence TherapeuticsSLN · Nasdaq | 1 asset: 1 Ph 2 | ZerlasiranPhase 2 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record | $2.8B | $248MSep 2026 | ~22.4 qtrs | $36M |
COMPASS PathwaysCMPS · Nasdaq | 1 asset: 1 Ph 3 | Psilocybin (COMP360)Phase 3 · Major Depressive DisorderReliable signal | Nov 2028Psilocybin (COMP360) · Phase 2/3 | $1.1B | $444MSep 2026 | ~10.1 qtrs | $109M |
Autolus Therapeutics plcAUTL · Nasdaq | 1 asset: 1 approved | Approved assets only | Sep 2027obecabtagene autoleucel · Phase 1 | $282M | $250MSep 2026 | ~5.7 qtrs | $116M |
Mereo BioPharmaMREO · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | setrusumabPhase 3 · Osteogenesis ImperfectaPartial signal | Jan 2027setrusumab · Phase 3 | $46M | $26MSep 2026 | ~4.0 qtrs | $13M |
Arecor LimitedAREC · AIM | 1 asset: 1 Ph 1 | Insulin aspart (AT278)Phase 1 · Type 2 DiabetesPartial signal | None on record | — | — | — | — |
BicycleTx LimitedBCYC · Nasdaq | 2 assets: 2 Ph 2 | Nuzefatide pevedotinPhase 2 · Pancreatic Ductal Adenocarcinoma | 31 Dec 2026Nuzefatide pevedotin · Phase 1/2 | — | $470MSep 2026 | ~10.7 qtrs | $175M |
Immunocore Holdings plcIMCR · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | brenetafuspPhase 3 · Cutaneous Melanoma | 16 Oct 2027brenetafusp · Phase 3 | — | $901MSep 2026 | 10+ years | $289M |
Roivant Sciences Ltd.ROIV · Nasdaq | 3 assets: 1 approved, 2 Ph 3 | ImeroprubartPhase 3 · Myasthenia Gravis | Dec 2026Mosliciguat · Phase 2 | — | $4.2BSep 2026 | 10+ years | ~$678M |
Tiziana Life Sciences Ltd.TLSA · Nasdaq | 1 asset: 1 Ph 2 | ForalumabPhase 2 · Multiple Sclerosis | 1 Apr 2027Foralumab · Phase 2 | — | $3.7MDec 2024 | ~9.7 qtrs | $5.2M |
Accord HealthcarePrivate | 2 assets: 1 approved, 1 Ph 3 | SerplulimabPhase 3 · Non-Small Cell Lung CancerReliable signal | 30 Dec 2026Serplulimab · Phase 1 | — | — | — | — |
Advanz PharmaPrivate | 4 assets: 3 approved, 1 other | Aflibercept (Mynzepli)Age-Related Macular Degeneration | None on record | — | — | — | — |
Almac DiscoveryPrivate | 1 asset: 1 Ph 2 | ZedoresertibPhase 1/2 · HR+/HER2- Metastatic Breast Cancer | Dec 2027Zedoresertib · Phase 1 | — | — | — | — |
Amandala Neuro LimitedPrivate | 1 asset: 1 Ph 2 | ELE-101Phase 1/2 · Major Depressive Disorder | None on record | — | — | — | — |
Apollo TherapeuticsPrivate | 4 assets: 3 Ph 2, 1 Ph 1 | camoteskimabPhase 2 · Atopic DermatitisPartial signal | Jul 2027APL-4098 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 2 | RAD101Phase 2 · Brain Metastases | None on record | — | — | — | — | |
CNX TherapeuticsPrivate | 1 asset: 1 Ph 3 | NabiximolsPhase 3 · Multiple SclerosisPartial signal | None on record | — | — | — | — |
Grey Wolf TherapeuticsPrivate | 1 asset: 1 Ph 2 | GRWD5769Phase 1/2 · Non-Small Cell Lung Cancer | 30 Apr 2027GRWD5769 · Phase 1/2 | — | — | — | — |
Imperial College LondonPrivate | 1 asset: 1 Ph 2 | RAD101Phase 2 · Brain Metastases | None on record | — | — | — | — |
MicrobioticaPrivate | 1 asset: 1 Ph 1 | MB310Phase 1 · Ulcerative ColitisPartial signal | None on record | — | — | — | — |
Oxford Vacmedix UK Ltd.Private | 1 asset: 1 Ph 1 | OVM-200Phase 1 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
PharmanoviaPrivate | 3 assets: 2 approved, 1 Ph 3 | Diazepam (Libervant)Phase 3 · EpilepsyWeak signal | Dec 2026Solriamfetol · Phase 3 | — | — | — | — |
Pheon TherapeuticsPrivate | 1 asset: 1 Ph 1 | PHN-012Phase 1 · Non-Small Cell Lung Cancer | Sep 2027PHN-012 · Phase 1 | — | — | — | — |
RezeraPrivate | 1 asset: 1 Ph 2 | RuvonoflastPhase 2 · ObesityPartial signal | None on record | — | — | — | — |
Rosemont PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.